Condition
Herpesvirus 4, Human
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
Trial Status
Completed2
Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06463392Recruiting
Deep Learning-based sbORN Diagnostic Model
NCT06321939Recruiting
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
NCT00342147Completed
Family Study of Head and Neck Cancers in Taiwan
NCT01257100Terminated
Environmental and Genetic Determinants of NPC
NCT01196520Completed
Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Showing all 5 trials